Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Benoît, You"'
Autor:
Anne-Claire Hardy-Bessard, Fabien Brocard, Florian Clatot, Alain Lortholary, Benoît You, Julien Grenier, Jérôme Martin-Babau, Brigitte Lucas, Jérôme Meunier, Jean-Marc Ferrero, Aude-Marie Savoye, Adina Marti, Raymond Despax, Isabelle Moullet, George Emile
Publikováno v:
Breast, Vol 54, Iss , Pp 256-263 (2020)
Purpose: Combining bevacizumab with paclitaxel significantly improves progression-free survival (PFS) versus paclitaxel alone in HER2-negative metastatic breast cancer (MBC). Eribulin is active and tolerable in pretreated MBC. To assess whether eribu
Externí odkaz:
https://doaj.org/article/5f30d47341a749e8b8dd8bab88cebbdc
Autor:
Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, Nicolas Delanoy, Florence Joly, Alain Lortholary, Benoît You, Patrick Bouchaert, Emmanuelle Malaurie, Sebastien Gouy, Marie-Christine Kaminsky, Jérôme Meunier, Jérôme Alexandre, Dominique Berton, Nadine Dohollou, Coraline Dubot, Anne Floquet, Laure Favier, Laurence Venat-Bouvet, Michel Fabbro, Christophe Louvet, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Christophe Desauw, Francesco Del Piano, Marianne Leheurteur, Nathalie Bonichon-Lamichhane, Mansour Rastkhah, Philippe Follana, Justine Gantzer, Isabelle Ray-Coquard, Eric Pujade-Lauraine
Publikováno v:
Gynecologic Oncology. 170:186-194
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14cec58707cd7c4b5aefc675bf3bf5db
https://doi.org/10.1016/j.ygyno.2023.01.008
https://doi.org/10.1016/j.ygyno.2023.01.008
Detailed model equations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::381cb7ed8e0295b7d3641f2a9fb56901
https://doi.org/10.1158/0008-5472.22418387
https://doi.org/10.1158/0008-5472.22418387
Legends for Supplementary Figures S1 to S8m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::274c0fc0c0d5557dfa8bf915766af241
https://doi.org/10.1158/0008-5472.22418366
https://doi.org/10.1158/0008-5472.22418366
Figures S4, S5 and S6, in that order : survival and power for (respectively) low, medium and high PK variability.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37c1d1d47acd24d1ed0ea922e360b3e4
https://doi.org/10.1158/0008-5472.22418372
https://doi.org/10.1158/0008-5472.22418372
Autor:
Veronique Trillet-Lenoir, Samira Ziti-Ljajic, Karen Soussan-Lazard, Sylvie Assadourian, Laure Favier, Claire Falandry, Pierre Fumoleau, Benoît You, Sylvie Zanetta, Gilles Freyer, Nicolas Isambert
PDF file - 68K, Individual median of free to VEGF-bound aflibercept Ctrough ratio observed from cycle.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::299a91350a3f89d1371673a8e01f622a
https://doi.org/10.1158/1078-0432.22447157
https://doi.org/10.1158/1078-0432.22447157
Autor:
Veronique Trillet-Lenoir, Samira Ziti-Ljajic, Karen Soussan-Lazard, Sylvie Assadourian, Laure Favier, Claire Falandry, Pierre Fumoleau, Benoît You, Sylvie Zanetta, Gilles Freyer, Nicolas Isambert
Purpose: This phase I study cohort investigated aflibercept in combination with docetaxel in patients with advanced solid tumors.Materials and Methods: Eligible patients had metastatic or nonresectable cancer for which docetaxel was considered approp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b31f4468f14cb2987718d79ba87bf3f2
https://doi.org/10.1158/1078-0432.c.6520991.v1
https://doi.org/10.1158/1078-0432.c.6520991.v1
Autor:
Florence Joly, Michel Fabbro, Philippe Follana, Justine Lequesne, Jacques Medioni, Anne Lesoin, Jean-Sébastien Frenel, Sophie Abadie-Lacourtoisie, Anne Floquet, Laurence Gladieff, Benoît You, Céline Gavoille, Elsa Kalbacher, Mélanie Briand, Pierre-Emmanuel Brachet, Florence Giffard, Louis-Bastien Weiswald, Pierre-Alexandre Just, Cécile Blanc-Fournier, Alexandra Leconte, Bénédicte Clarisse, Alexandra Leary, Laurent Poulain
Publikováno v:
Gynecologic Oncology. 165:30-39
There are limited treatment options for ovarian cancer patients with early relapse after platinum chemotherapy. In preclinical studies, we previously demonstrated the promising activity of ABT-737, a Bcl-2/Bcl-xWe conducted a prospective multicenter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0790e53d64eee3f4c941fd997dd14f8
https://doi.org/10.1016/j.ygyno.2022.01.021
https://doi.org/10.1016/j.ygyno.2022.01.021
Autor:
Florence Joly, Michel Fabbro, Dominique Berton, Justine Lequesne, Amélie Anota, Alicja Puszkiel, Anne Floquet, Hélène Vegas, Hugues Bourgeois, Leïla Bengrine Lefevre, Benoît You, Fanny Pommeret, Alain Lortholary, Dominique Spaeth, Anne-Claire Hardy-Bessard, Cyril Abdeddaim, Marie-Christine Kaminsky-Forrett, Michel Tod, Jean-Emmanuel Kurtz, Francesco Del Piano, Jérôme Meunier, Nadia Raban, Jérome Alexandre, Marie-Ange Mouret-Reynier, Isabelle Ray-Coquard, Magali Provansal Gross, Pierre-Emmanuel Brachet
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, 2022, 166 (3), pp.389-396. ⟨10.1016/j.ygyno.2022.06.022⟩
Gynecologic Oncology, 2022, 166 (3), pp.389-396. ⟨10.1016/j.ygyno.2022.06.022⟩
Anti-angiogenic rechallenge with bevacizumab plus chemotherapy is effective in recurrent ovarian cancer (rOC); however, data are limited on tyrosine kinase inhibitors after progression on maintenance bevacizumab.In the randomized phase II TAPAZ trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::655dbf1d8d8bd14e892d16da08ad1540
https://pubmed.ncbi.nlm.nih.gov/35902297
https://pubmed.ncbi.nlm.nih.gov/35902297
Autor:
Laetitia Collet, Julien Péron, Frédérique Penault-Llorca, Pascal Pujol, Jonathan Lopez, Gilles Freyer, Benoît You
Publikováno v:
Cancers
Cancers, MDPI, 2022, 14 (3), pp.599. ⟨10.3390/cancers14030599⟩
Cancers, Vol 14, Iss 599, p 599 (2022)
Cancers, MDPI, 2022, 14 (3), pp.599. ⟨10.3390/cancers14030599⟩
Cancers, Vol 14, Iss 599, p 599 (2022)
International audience; Recently, OlympiAD and EMBRACA trials demonstrated the favorable efficacy/toxicity ratio of PARPi, compared to chemotherapy, in patients with HER2-negative metastatic breast cancers (mBC) carrying a germline BRCA mutation. PAR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b72baa00264f9a241190cfd880790a0
https://hal.archives-ouvertes.fr/hal-03595564
https://hal.archives-ouvertes.fr/hal-03595564